207 related articles for article (PubMed ID: 33036973)
1. Self-regulated hirudin delivery for anticoagulant therapy.
Xu X; Huang X; Zhang Y; Shen S; Feng Z; Dong H; Zhang C; Mo R
Sci Adv; 2020 Oct; 6(41):. PubMed ID: 33036973
[TBL] [Abstract][Full Text] [Related]
2. Laboratory assays for the evaluation of recombinant hirudin.
Walenga JM; Hoppensteadt D; Koza M; Wallock M; Pifarre R; Fareed J
Haemostasis; 1991; 21 Suppl 1():49-63. PubMed ID: 1894197
[TBL] [Abstract][Full Text] [Related]
3. Fibrin-targeted recombinant hirudin inhibits fibrin deposition on experimental clots more efficiently than recombinant hirudin.
Bode C; Hudelmayer M; Mehwald P; Bauer S; Freitag M; von Hodenberg E; Newell JB; Kübler W; Haber E; Runge MS
Circulation; 1994 Oct; 90(4):1956-63. PubMed ID: 7923685
[TBL] [Abstract][Full Text] [Related]
4. Platelet-Covered Nanocarriers for Targeted Delivery of Hirudin to Eliminate Thrombotic Complication in Tumor Therapy.
Zhang K; Ma Z; Li S; Zhang W; Foda MF; Zhao Y; Han H
ACS Nano; 2022 Nov; 16(11):18483-18496. PubMed ID: 36350264
[TBL] [Abstract][Full Text] [Related]
5. RGD-hirudin-based low molecular weight peptide prevents blood coagulation via subcutaneous injection.
Li YR; Huang YN; Zhao B; Wu MF; Li TY; Zhang YL; Chen D; Yu M; Mo W
Acta Pharmacol Sin; 2020 Jun; 41(6):753-762. PubMed ID: 31949293
[TBL] [Abstract][Full Text] [Related]
6. Hirudin as alternative anticoagulant--a historical review.
Markwardt F
Semin Thromb Hemost; 2002 Oct; 28(5):405-14. PubMed ID: 12420235
[TBL] [Abstract][Full Text] [Related]
7. Effect of hirudin on tissue plasminogen activator induced clot lysis.
Electricwala A; Atkinson T
Blood Coagul Fibrinolysis; 1990 Aug; 1(3):267-71. PubMed ID: 2129413
[TBL] [Abstract][Full Text] [Related]
8. Hirudin and derivatives as anticoagulant agents.
Markwardt F
Thromb Haemost; 1991 Jul; 66(1):141-52. PubMed ID: 1926044
[No Abstract] [Full Text] [Related]
9. The antithrombotic effect of a novel hirudin derivative after reconstruction of carotid artery in rabbits.
Lu WF; Mo W; Liu Z; Fu WG; Guo DQ; Wang YQ; Song HY
Thromb Res; 2010 Oct; 126(4):e339-43. PubMed ID: 20483158
[TBL] [Abstract][Full Text] [Related]
10. An objective perspective on recombinant hirudin: a new anticoagulant and antithrombotic agent.
Fareed J; Walenga JM; Iyer L; Hoppensteadt D; Pifarre R
Blood Coagul Fibrinolysis; 1991 Feb; 2(1):135-47. PubMed ID: 1772981
[TBL] [Abstract][Full Text] [Related]
11. Antithrombin effects of native and recombinant hirudins.
Markwardt F; Stürzebecher J; Glusa E
Biomed Biochim Acta; 1990; 49(5):399-404. PubMed ID: 2271010
[TBL] [Abstract][Full Text] [Related]
12. Distinct features of bivalent direct thrombin inhibitors, hirudin and bivalirudin, revealed by clot waveform analysis and enzyme kinetics in coagulation assays.
Wakui M; Fujimori Y; Nakamura S; Kondo Y; Kuroda Y; Oka S; Nakagawa T; Katagiri H; Murata M
J Clin Pathol; 2019 Dec; 72(12):817-824. PubMed ID: 31366633
[TBL] [Abstract][Full Text] [Related]
13. Development of recombinant hirudin as a therapeutic anticoagulant and antithrombotic agent: some objective considerations.
Walenga JM; Pifarre R; Hoppensteadt DA; Fareed J
Semin Thromb Hemost; 1989 Jul; 15(3):316-33. PubMed ID: 2688104
[No Abstract] [Full Text] [Related]
14. Investigation on recombinant hirudin via oral route.
Cen X; Ni J; Tan T; Liu X; Li C; Chen J; Huang Y; Zhu S; Bi Q
Peptides; 2006 Apr; 27(4):836-40. PubMed ID: 16469415
[TBL] [Abstract][Full Text] [Related]
15. Improving long circulation and procoagulant platelet targeting by engineering of hirudin prodrug.
Han HH; Zhang HT; Wang R; Yan Y; Liu X; Wang Y; Zhu Y; Wang JC
Int J Pharm; 2020 Nov; 589():119869. PubMed ID: 32919000
[TBL] [Abstract][Full Text] [Related]
16. The anticoagulant mechanism of action of recombinant hirudin (CGP 39393) in plasma.
Lindhout T; Blezer R; Hemker HC
Thromb Haemost; 1990 Nov; 64(3):464-8. PubMed ID: 2096492
[TBL] [Abstract][Full Text] [Related]
17. The antithrombotic and anticoagulant effects of a synthetic tripeptide and recombinant hirudin in various animal models.
Bacher P; Walenga JM; Iqbal O; Bajusz S; Breddin K; Fareed J
Thromb Res; 1993 Aug; 71(4):251-63. PubMed ID: 8236155
[TBL] [Abstract][Full Text] [Related]
18. Comparative studies on the anticoagulant and protease generation inhibitory actions of newly developed site-directed thrombin inhibitory drugs. Efegatran, argatroban, hirulog, and hirudin.
Callas DD; Hoppensteadt D; Fareed J
Semin Thromb Hemost; 1995; 21(2):177-83. PubMed ID: 7660140
[TBL] [Abstract][Full Text] [Related]
19. Sustained antithrombotic activity of hirudin after its plasma clearance: comparison with heparin.
Agnelli G; Renga C; Weitz JI; Nenci GG; Hirsh J
Blood; 1992 Aug; 80(4):960-5. PubMed ID: 1498336
[TBL] [Abstract][Full Text] [Related]
20. Additive effect of the combined administration of low molecular weight heparin and recombinant hirudin on thrombus growth in a rabbit jugular vein thrombosis model.
Biemond BJ; Levi M; Nurmohamed MT; Büller HR; ten Cate JW
Thromb Haemost; 1994 Sep; 72(3):377-80. PubMed ID: 7855787
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
